CA2816448A1 - Treatment of heart failure with normal ejection fraction - Google Patents

Treatment of heart failure with normal ejection fraction Download PDF

Info

Publication number
CA2816448A1
CA2816448A1 CA2816448A CA2816448A CA2816448A1 CA 2816448 A1 CA2816448 A1 CA 2816448A1 CA 2816448 A CA2816448 A CA 2816448A CA 2816448 A CA2816448 A CA 2816448A CA 2816448 A1 CA2816448 A1 CA 2816448A1
Authority
CA
Canada
Prior art keywords
patients
exercise
perhexiline
cardiac
diastolic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2816448A
Other languages
English (en)
French (fr)
Inventor
Houman Ashrafian
Michael Paul Frenneaux
Original Assignee
Heart Metabolics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Heart Metabolics Ltd filed Critical Heart Metabolics Ltd
Publication of CA2816448A1 publication Critical patent/CA2816448A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4458—Non condensed piperidines, e.g. piperocaine only substituted in position 2, e.g. methylphenidate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cardiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
CA2816448A 2009-05-20 2009-05-20 Treatment of heart failure with normal ejection fraction Abandoned CA2816448A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/GB2009/050539 WO2010133815A1 (en) 2009-05-20 2009-05-20 Treatment of heart failure with normal ejection fraction

Publications (1)

Publication Number Publication Date
CA2816448A1 true CA2816448A1 (en) 2010-11-25

Family

ID=41213178

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2816448A Abandoned CA2816448A1 (en) 2009-05-20 2009-05-20 Treatment of heart failure with normal ejection fraction

Country Status (11)

Country Link
US (3) US8440697B2 (enExample)
EP (1) EP2432470A1 (enExample)
JP (1) JP2012527438A (enExample)
CN (1) CN102573844A (enExample)
AU (1) AU2009346606B2 (enExample)
BR (1) BRPI0924398A2 (enExample)
CA (1) CA2816448A1 (enExample)
IL (1) IL216362A0 (enExample)
MX (1) MX2011012310A (enExample)
WO (1) WO2010133815A1 (enExample)
ZA (1) ZA201109332B (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0405381D0 (en) 2004-03-10 2004-04-21 Univ Wales Medicine A method and means for treating heart failure
WO2010133815A1 (en) 2009-05-20 2010-11-25 Heart Metabolics Limited Treatment of heart failure with normal ejection fraction
GB0908193D0 (en) 2009-05-13 2009-06-24 Albright Patents Treatment of disease state
US10137093B2 (en) 2011-08-16 2018-11-27 Cardiora Pty Ltd. Milrinone controlled-release formulation
WO2014036603A1 (en) * 2012-09-05 2014-03-13 Adelaide Research & Innovation Pty Ltd Uses of (-)-perhexiline
BR112017013015A2 (pt) * 2014-12-22 2018-03-06 Cardiora Pty Ltd método de tratamento de um paciente que possui falência cardíaca com fração de ejeção preservada (hfpef)
MX2019007125A (es) 2016-12-15 2019-09-16 Baxter Int Sistema y metodo para monitorizar y determinar parametros de paciente a partir de forma de onda venosa detectada.
US11039754B2 (en) 2018-05-14 2021-06-22 Baxter International Inc. System and method for monitoring and determining patient parameters from sensed venous waveform

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPN380695A0 (en) 1995-06-23 1995-07-20 Queen Elizabeth Hospital, The Methods related to the treatment of and isolation of compounds for treatment of ischaemic conditions
US20030162824A1 (en) 2001-11-12 2003-08-28 Krul Elaine S. Methods of treating or preventing a cardiovascular condition using a cyclooxygenase-1 inhibitor
CL2004000366A1 (es) 2003-02-26 2005-01-07 Pharmacia Corp Sa Organizada B USO DE UNA COMBINACION DE UN COMPUESTO DERIVADO DE PIRAZOL INHIBIDOR DE QUINASA p38, Y UN INHIBIDOR DE ACE PARA TRATAR DISFUNCION RENAL, ENFERMEDAD CARDIOVASCULAR Y VASCULAR, RETINOPATIA, NEUROPATIA, EDEMA, DISFUNCION ENDOTELIAL O INSULINOPATIA.
GB0405381D0 (en) 2004-03-10 2004-04-21 Univ Wales Medicine A method and means for treating heart failure
WO2005097121A1 (en) 2004-04-06 2005-10-20 Angiogenetics Sweden Ab Angiogenesis-affecting compounds and methods of use thereof
DE602006011363D1 (de) 2005-12-01 2010-02-04 Hoffmann La Roche Heteroaryl-substituierte piperidin-derivate als l-cpt1-hemmer
ITRM20060090A1 (it) 2006-02-22 2007-08-23 Sigma Tau Ind Farmaceuti Nuovi composti inibitori cpt a livello del snc come farmaci antidiabetici e o antiobesita
WO2010133815A1 (en) 2009-05-20 2010-11-25 Heart Metabolics Limited Treatment of heart failure with normal ejection fraction
GB0723100D0 (en) * 2007-11-23 2008-01-02 Heart Metabolics Ltd Treatment of HFnEF
GB0908193D0 (en) 2009-05-13 2009-06-24 Albright Patents Treatment of disease state
US20140019207A1 (en) 2012-07-11 2014-01-16 Sap Ag Interactive in-memory based sales forecasting
WO2014036603A1 (en) 2012-09-05 2014-03-13 Adelaide Research & Innovation Pty Ltd Uses of (-)-perhexiline
WO2015131231A1 (en) 2014-03-03 2015-09-11 Adelaide Research & Innovation Pty Ltd Methods for using (-)-perhexiline

Also Published As

Publication number Publication date
ZA201109332B (en) 2012-08-29
AU2009346606B2 (en) 2016-06-02
US8440697B2 (en) 2013-05-14
US20130210719A1 (en) 2013-08-15
JP2012527438A (ja) 2012-11-08
EP2432470A1 (en) 2012-03-28
IL216362A0 (en) 2012-01-31
US9468634B2 (en) 2016-10-18
US20130210720A1 (en) 2013-08-15
US20100331364A1 (en) 2010-12-30
MX2011012310A (es) 2012-04-11
WO2010133815A1 (en) 2010-11-25
CN102573844A (zh) 2012-07-11
AU2009346606A1 (en) 2012-01-19
US9457017B2 (en) 2016-10-04
BRPI0924398A2 (pt) 2019-09-24

Similar Documents

Publication Publication Date Title
US9468634B2 (en) Treatment of heart failure
AU2010247120B2 (en) Perhexiline for use in the treatment of hypertrophic cardiomyopathy (HCM)
Kahn et al. Radionuclide assessment of left ventricular diastolic filling in diabetes mellitus with and without cardiac autonomic neuropathy
US8697677B2 (en) Perhexiline for treating chronic heart failure
Lundström et al. Differential effects of xamoterol and verapamil on ventricular rate regulation in patients with chronic atrial fibrillation
WO2009066085A1 (en) Treatment of heart failure with normal ejection fraction
JP2015147787A (ja) 正常駆出率心不全の治療
Ishizu et al. Left ventricular longitudinal strain as a marker for point of no return in hypertensive heart failure treatment
Iwashima et al. Regression of cardiac hypertrophy in type 2 diabetes with hypertension by candesartan
CA3179788C (en) Pharmaceutical composition for treatment of hypertrophic cardiomyopathy and treatment method using same composition
US20250295639A1 (en) Methods for treating heart diseases
RU2195179C2 (ru) Способ диагностики жизнеспособного миокарда
US20230190708A1 (en) Pharmaceutical composition for treatment of hypertrophic cardiomyopathy and treatment method using same composition
Aqel et al. Thebesian venous lake
WO2017021283A1 (en) Substance selected among midodrine, a pharmaceutical salt and an active metabolite thereof, for use in the treatment of obstructive cardiopathy
Abd El Azeem et al. Evaluation of aggressive heart rate reduction in patients with stable angina
Energy Exercise Physiology
Damy et al. ORIGINAL ARTICLE Pharmacokinetic and pharmacodynamic interactions between metoprolol and dronedarone in extensive and poor CYP2D6 metabolizers healthy subjects.
NEGREA THE EFFECTS OF ANGIOTENSIN RECEPTOR BLOCKERS ON LEFT VENTRICULAR MASS IN HYPERTENSIVE PATIENTS

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20140502

FZDE Discontinued

Effective date: 20180523